Načítá se...
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
Improved personalized adjustment of primary therapy to the perceived risk of relapse by using new prognostic markers for treatment stratification may be beneficial to patients with acute lymphoblastic leukemia (ALL). Here, we review the advances that have shed light on the role of IKZF1 aberration a...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7019035/ https://ncbi.nlm.nih.gov/pubmed/31821407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000813 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|